Evidence for a role of macrophage migration inhibitory factor in vascular disease

Zhiping Chen1, Masashi Sakuma, Alexandre C Zago

  • 1Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass 02115, USA.

Abstract

Insights

Blocking macrophage migration inhibitory factor (MIF) after angioplasty in mice with atherosclerosis reduced vascular inflammation, cell proliferation, and neointimal thickening, suggesting MIF as a therapeutic target.

Area of Science:

  • Vascular Biology
  • Immunology
  • Cardiovascular Research

Background:

  • Inflammation is critical in atherosclerosis and restenosis.
  • Macrophage migration inhibitory factor (MIF) is a proinflammatory cytokine found in vascular cells.
  • In vivo evidence for MIF's role in vascular injury and repair was lacking.

Purpose of the Study:

  • To investigate the effect of blocking MIF on the response to experimental angioplasty.
  • To assess MIF's direct role in vascular injury and repair processes.

Main Methods:

  • Experimental angioplasty was performed on atherosclerosis-susceptible mice (LDL receptor-deficient).
  • Mice received either a neutralizing anti-MIF antibody or an isotype control antibody.
  • Vascular remodeling, intimal thickening, inflammation, cellular proliferation, and apoptosis were measured at 7 and 28 days post-angioplasty.

Main Results:

  • Anti-MIF treatment significantly reduced intimal thickening and the intima/media area ratio compared to controls.
  • MIF blockade led to decreased vascular inflammation and cellular proliferation.
  • Increased apoptosis was observed in vessels treated with anti-MIF after injury.

Conclusions:

  • Neutralizing MIF bioactivity effectively reduces vascular inflammation, proliferation, and neointimal thickening post-angioplasty in susceptible mice.
  • These findings highlight MIF's role in vascular disease.
  • Targeting MIF may offer novel therapeutic strategies for preventing atherosclerosis and restenosis.